The MemAID was a 24-week trial of INI treatment with 24-weeks of follow-up, and this Safety sub-study in subcutaneous insulin treated T2DM has demonstrated the long-term safety and feasibility of this emerging treatment of diabetes complications in the brain. This evidence concerns the gene INS and diabetes mellitus.